Тозинамеран - tozinameran: раствор для инъекций - Вакцина мРНК COVID-19 BNT162b2 концентрат



| 7 Апреля 2022, 11:35

Решение

Информация для получателей вакцины Pfizer/BioNTech против COVID-19 из Великобритании (Положение 174)

Обновлено 25 марта 2022 г.

COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection tozinameran

This medicinal product has been given authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines & Healthcare products Regulatory Agency. It does not have a marketing authorisation, but this temporary authorisation grants permission for the medicine to be used for active immunisation to prevent COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 12 years of age and over.